DNA Methylation & Cancer: Epigenetic Mechanisms

Added:

The Somatic Mutation Theory and Epigenetic 'Passenger' Hypothesis

While the epigenetic model highlights aberrant DNA methylation as a primary driver of oncogenesis, an alternative perspective argues that genetic mutations remain the true initiators of cancer (the Somatic Mutation Theory). From this viewpoint, many disrupted DNA methylation patterns are secondary "passenger" events rather than causal "drivers" of malignancy. Critics point out that altered methylation is often a downstream consequence of genetic mutations in chromatin-modifying genes (such as DNMT3A, TET2, or IDH1/2) or a byproduct of rapid cell division and cellular aging. Furthermore, some researchers caution against the therapeutic promise of global demethylating agents, noting that non-specific demethylation can cause genomic instability by reactivating transposable elements or inadvertently upregulating oncogenes. Consequently, this perspective suggests that DNA methylation changes are largely phenotypic markers of genetic instability rather than independent, primary initiators of cancer.

The basic structure of DNA, specifically the four nitrogenous bases (adenine, thymine, cytosine, guanine) and how gene expression is traditionally regulated.
The foundational concept of epigenetics, defined as heritable changes in gene expression that do not involve alterations to the underlying DNA sequence.
The biological hallmarks of cancer, including the roles of oncogenes and tumor suppressor genes in regulating the cell cycle.
Chromatin structure and organization, specifically how DNA wraps around histone proteins to form nucleosomes and control genetic accessibility.
Advanced epigenetic mechanisms, such as histone post-translational modifications (acetylation, methylation) and non-coding RNA regulation in oncogenesis.
Epigenetic therapies (epidrugs), including DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors used in cancer treatment.
The use of DNA methylation patterns as clinical biomarkers for early cancer detection, prognosis, and liquid biopsy technologies.
Environmental epigenetics, exploring how lifestyle factors, diet, toxins, and aging influence the epigenome and alter cancer susceptibility.
243.9K views4.1Klikes5:16@garvaninstituteOriginal Release: 2015-11-12

DNA methylation is an epigenetic process where methyl groups are added to cytosine-guanine (CpG) sites in DNA, primarily mediated by DNA methyltransferases (DNMT1 for maintenance and DNMT3a/b for de novo methylation), and regulated by TET enzymes that can remove methyl groups; in normal cells, promoter regions are typically unmethylated allowing gene expression, but in cancer, this balance is disrupted through hypermethylation of promoter CpG islands (silencing tumor suppressor genes) and widespread hypomethylation across the genome, creating a distinctive epigenetic signature that can be used for cancer detection.